Message from the CEO

Suzanne Bruhn
At Promedior, our mission is to develop and advance targeted therapeutics to address the significant unmet needs of patients with diseases involving fibrosis. We are creating our drug platform to be uniquely capable of preventing and reversing the pathological processes in fibrotic diseases—such as idiopathic pulmonary fibrosis, myelofibrosis, and in fibrovascular eye diseases—that have few treatment options and are so devastating to patients and their families.

I am excited to lead the talented and passionate team we are building at Promedior. We value each member of our team and seek to recruit dedicated employees who are inspired to help us fulfill the potential of our platform to make a significant difference for patients.

Building on our strong scientific foundation, we are energized to take on the many challenges we know lie ahead of us as we advance through human clinical studies in order to commercialize our first-in-class Pentraxin-2 therapeutics. While we are proud of our team and accomplishments, we clearly recognize that our success will be amplified and accelerated by collaboration. We are strategically committed to creating alliances to ensure that our drug candidates can most quickly and broadly be used to address unmet needs for patients with fibrotic diseases.

Thank you for visiting our website. We welcome your interest in Promedior: our people, our platform, and our dedication to patients.


Suzanne L. Bruhn, Ph.D.
President and CEO
Promedior, Inc.


At Promedior, we are focused on developing novel therapeutics to address the unmet needs of patients with fibrosis. Learn More >